Design and Synthesis of Anemoside B4 Derivatives as Pyruvate Carboxylase-Targeting Therapeutic Agents for Atopic Dermatitis
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Heng Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Soochow University, Suzhou, Jiangsu215123, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Drug Design, Pyruvate Carboxylase, Saponins. Die Arbeit nennt 80 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
Although injectable anemoside B4 (AB4) has therapeutic potential for atopic dermatitis (AD), its clinical use is restricted by safety and pharmacokinetic issues. Therefore, we designed 42 AB4 derivatives, established a preliminary SAR for anti-inflammatory and antiallergic activities, and selected three promising compounds for in vivo evaluation in an AD mouse model, leading to the identification of B4-39 as the lead compound. In a DNCB-induced AD mouse model, topical B4-39 (6.6 mg/kg) was more effective than dexamethasone and free from its side effects, while matching the efficacy of crisaborole at a much lower dose and providing better skin barrier repair. Mechanistically, B4-39 targets pyruvate carboxylase (PC)─a novel therapeutic target in AD─modulating the TCA cycle to suppress dendritic cell activation and concurrently inhibiting NF-κB and NLRP3 inflammasome signaling. Given its enhanced efficacy, steroid-sparing safety, novel PC-targeted action, and favorable topical delivery, B4-39 is a highly promising candidate for AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Suzhou Medical College of Soochow University, Soochow University, Suzhou, Jiangsu215123, China.
- National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, Mississippi38677, United States.
- Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan450046, China.
ORCID-Profile: Jianping Zhao, Bin Huang, Qiongming Xu
Förderung
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Li, H., Du, Y., Li, Q., Zhang, J., Zhao, J., Niu, M., Su, S., Xie, A., He, W., Huang, G., Xiao, L., Huang, Z., Khan, I. A., Yang, S., Feng, S., Huang, B., Xu, Q., & Liu, Y. (2026). Design and Synthesis of Anemoside B4 Derivatives as Pyruvate Carboxylase-Targeting Therapeutic Agents for Atopic Dermatitis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00451
Vancouver
Li H, Du Y, Li Q, Zhang J, Zhao J, Niu M, et al. Design and Synthesis of Anemoside B4 Derivatives as Pyruvate Carboxylase-Targeting Therapeutic Agents for Atopic Dermatitis. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00451
BibTeX
@article{Li2026,
author = {Li, Heng and Du, Yexin and Li, Qiurong and Zhang, Junlei and Zhao, Jianping and Niu, Mengxin and Su, Shuying and Xie, Aocheng and He, Wei and Huang, Guiyan and Xiao, Lihua and Huang, Zhichao and Khan, Ikhlas A and Yang, Shilin and Feng, Suxiang and Huang, Bin and Xu, Qiongming and Liu, Yanli},
title = {Design and Synthesis of Anemoside B4 Derivatives as Pyruvate Carboxylase-Targeting Therapeutic Agents for Atopic Dermatitis},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00451}
}
EUVIMED